Topic

New York

A collection of 427 issues

Besponsa (Inotuzumab Ozogamicin) Approval with Aetna CVS Health in New York: Complete Guide to Prior Authorization, Appeals, and State Protections

Answer Box: Getting Besponsa Covered by Aetna CVS Health in New York Yes, Aetna CVS Health covers Besponsa (inotuzumab ozogamicin) in New York with prior authorization for CD22-positive B-cell precursor ALL. The fastest path to approval: (1) Your oncologist submits the Aetna Besponsa precertification form electronically with CD22+ lab results
5 min read

Taltz (ixekizumab) Approval with UnitedHealthcare in New York: Complete Guide with Forms, Appeals, and Patient Scripts

Quick Answer: Getting Taltz (ixekizumab) Covered by UnitedHealthcare in New York Yes, UnitedHealthcare covers Taltz (ixekizumab) in New York, but requires prior authorization with documented step therapy failure. You must first try preferred biologics like Humira or Enbrel, plus complete TB screening. Fastest path: Have your dermatologist or rheumatologist submit
7 min read

How to Get Strensiq (Asfotase Alfa) Covered by Cigna in New York: Complete PA Guide and Appeals Strategy

Answer Box: Getting Strensiq Covered by Cigna in New York Eligibility: Cigna covers Strensiq (asfotase alfa) for pediatric-onset hypophosphatasia (HPP) only—perinatal, infantile, or juvenile onset before age 18. Required documentation: ALPL gene mutation, low alkaline phosphatase levels, and specialist prescription. First step: Contact your pediatric endocrinologist or geneticist to
5 min read

How to Get Zolgensma Covered by UnitedHealthcare in New York: Prior Authorization, Appeals, and Cost-Saving Strategies

Answer Box: Getting Zolgensma Covered by UnitedHealthcare in New York Fastest Path to Approval: UnitedHealthcare requires prior authorization for Zolgensma with genetic confirmation, anti-AAV9 antibody testing (≤1:50), and documentation of failed alternative therapies or contraindications. Submit through OptumRx with complete medical records. If denied, file internal appeal within 180
6 min read